The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $16.62

Today's change-0.72 -4.15%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $16.62

Today's change-0.72 -4.15%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Boston Scientific Corp down (U.S.)$0.72

Boston Scientific Corp closed sharply lower Friday, dropping (U.S.)$0.72 or 4.15% to (U.S.)$16.62. Over the last five days, shares have lost 5.19% and are down 9.87% for the last year to date. This security has outperformed the S&P 500 by 18.69% during the last year.

Key company metrics

  • Open(U.S.) $17.25
  • Previous close(U.S.) $17.34
  • High(U.S.) $17.43
  • Low(U.S.) $16.58
  • Bid / Ask-- / --
  • YTD % change-9.87%
  • Volume17,077,341
  • Average volume (10-day)13,122,026
  • Average volume (1-month)10,683,234
  • Average volume (3-month)10,154,655
  • 52-week range(U.S.) $14.18 to (U.S.) $19.06
  • Beta0.99
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward16.05×
  • Forward PEG1.23×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.18
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-3.20%

Although this company's net profit margin is negative, it is above the industry average and implies that Boston Scientific Corp is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue1,8881,8431,7681,887
Total other revenue--------
Total revenue1,8881,8431,7681,887
Gross profit1,3541,3111,2561,337
Total cost of revenue534532512550
Total operating expense2,1871,6241,7442,379
Selling / general / administrative720696660746
Research & development221220192208
Depreciation / amortization131116113111
Interest expense (income), net operating--------
Unusual expense (income)56442250739
Other operating expenses, total17181725
Operating income-29921924-492
Interest income (expense), net non-operating-58-106-60-55
Gain (loss) on sale of assets--------
Other--------
Income before tax-367105-51-554
Income after tax-198102-1-299
Income tax, total-1693-50-255
Net income-198102-1-299
Total adjustments to net income--------
Net income before extra. items-198102-1-299
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-198102-1-299
Inc. avail. to common incl. extra. items-198102-1-299
Diluted net income-198102-1-299
Dilution adjustment------0
Diluted weighted average shares1,3441,3621,3341,327
Diluted EPS excluding extraordinary itemsvalue per share-0.150.070.00-0.23
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.130.100.120.14